Bijan Salehizadeh is co-founder and managing director of NaviMed Capital, a Washington, D.C.-based private investment firm focused exclusively on the healthcare industry, where he focuses on growth capital and private equity healthcare investments in healthcare IT and healthcare services.
“Managing behavioral health comorbidities is key to chronic conditions, and yet our system is not oriented towards doing that. Our view for the fund is we would want to start on delivery of care and back teams that know how to deploy IT efficiently…It’s complex to manage behavioral health,” said Salehizadeh in an interview with MedCity News on NaviMed’s investment priorities.
“Managing behavioral health comorbidities is key to chronic conditions and yet our system is not oriented towards doing that.” –Bijan Salehizadeh
“You have to start with the delivery of care to make those handoffs more efficient. That is the model we are focused on.”
A doctor by training, Salehizadeh has nearly 15 years in healthcare operating and investment experience. Prior to co-founding NaviMed, he was a General Partner at Highland Capital Partners and held management and operational roles at MedTronic and HealthCentral.
He is currently on the board of directors and advisory committees of numerous healthcare data and product companies including Auris Surgical, Hyperion Therapeutics (IPO), Kyruus, and Procured Health, and has sourced or been actively involved in investments in AVEO Oncology (IPO), Baronova, BÂRRX Medical (sold to Covidien), Conor Medsystems (IPO; sold to Johnson & Johnson), and Pharmaca Integrative Pharmacy.
Salehizadeh is a graduate of the Kauffman Fellows Program, a prestigious leadership development program for venture capitalists.